Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.68 |
| ▸ | PPARG | P37231 | 4/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 6/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440723 | 1.00 | PPARA (0.68) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL199415 | 1.00 | PPARA (0.68) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL4797933 | 0.94 | PPARG (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL4094724 | 0.94 | PPARG (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL8976947 | 0.93 | PPARA (0.60) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3821796 | 0.92 | PPARA (0.60) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL20187250 | 0.90 | CTSS (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3840582 | 0.90 | PPARG (0.58) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL18228983 | 0.90 | CTSS (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL10034081 | 0.90 | PPARG (0.60) | PPARAPPARGACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4538258-A1 | IMIDAZOLIDINYL VANILLIC ACID ETHER DERIVATIVE AND USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240368158-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4392417-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| CN-117881671-A | Kinase modulators, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-1497450-A2 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE ENZYMATIC ACTIVITY | Sunesis Pharmaceuticals, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| US-20040005632-A1 | Methods for identifying compounds that modulate enzymatic activity | SUNESIS PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003087054-A2 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE ENZYMATIC ACTIVITY | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-5952381-A | SELECTIVELY INHIBITING OR ANTAGONIZING THE INTEGRINS; ANTITUMOR AGENTS, ANTIARTHRITIC AGENTS, VIRICIDES, MICROBIOCIDES; TREATING OSTEOPOROSIS, SKIN DISORDERS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | CYP4B1, CYP2B6, UGT2B7 | PPARA 1198/4885PPARG 1356/4885ACE 2447/4885 |
| US-20040005632-A1 | Methods for identifying compounds that modulate enzymatic activity | RNASE1, GBA3, AADAC | PPARA 3650/4885PPARG 3451/4885ACE 247/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | PPARA 265/4885PPARG 184/4885ACE 4298/4885 |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | PPARA 4384/4885PPARG 2882/4885ACE 4710/4885 |
| US-20240368158-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | FLT3, PHKG1, LTK | PPARA 2571/4885PPARG 1363/4885ACE 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.